
This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

The Synthesis and Antiviral Activity of (E)-5-(2-Nitrovinyl)uridine and (E)-5-(2-Nitrovinyl)-2'-deoxyuridine

R. F. Whale^a; V. Bou^b; P. L. Coe^a; R. T. Walker^a

^a School of Chemistry, University of Birmingham, Birmingham ^b Departament de Quimica Organica, Barcelona, Spain

To cite this Article Whale, R. F. , Bou, V. , Coe, P. L. and Walker, R. T.(1992) 'The Synthesis and Antiviral Activity of (E)-5-(2-Nitrovinyl)uridine and (E)-5-(2-Nitrovinyl)-2'-deoxyuridine', Nucleosides, Nucleotides and Nucleic Acids, 11: 2, 595 — 602

To link to this Article: DOI: 10.1080/07328319208021728 URL: http://dx.doi.org/10.1080/07328319208021728

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

THE SYNTHESIS AND ANTIVIRAL ACTIVITY OF(E)-5-(2-NITROVINYL)URIDINE AND
(E)-5-(2-NITROVINYL)-2'-DEOXYURIDINE**

R.F. Whale¹, V. Bou², P.L. Coe¹ and R.T. Walker^{1*}

- 1. School of Chemistry, University of Birmingham, PO Box 363, Birmingham, B15 2TT
- Departament de Quimica Organica, Martif 1, Franques, 1-11, E-08028, Barcelona, Spain

<u>ABSTRACT</u>: The protection of the sugar moiety of a 5-formyluracil nucleoside with acid-labile protecting groups allows for the deprotection of the sugar of a subsequently formed nucleoside possessing a 5-nitrovinyl side-chain. The synthesis and antiviral activity of (E)-5-(2-nitrovinyl)-uridine and (E)-5-(2-nitrovinyl)-2'-deoxyuridine are reported.

INTRODUCTION

More than a decade ago, (E)-5-(2-bromoviny1)-2'-deoxyuridine (BVDU, 1 was synthesized and its antiviral activity against Herpes Simplex Virus Type 1² (HSV-1) and Varicella Zoster virus (VZV) were reported. The minimum inhibitory concentrations (MIC) of BVDU were found to be 0.007 and 0.002 μ g ml⁻¹ against these viruses respectively and with this lead many compounds have since been synthesized. Although few of the

HO OH R

$$A = Br$$
 $A = OH$
 $A = H$

^{**} This paper is dedicated to the memory of Professor Tohru Ueda.

analogues obtained showed as good or better activity, the synthesis of 5-substituted vinylic 2'-deoxynucleoside analogues are still occasionally reported. 5,6 Few of the published analogues were ribonucleosides and therefore we determined to synthesize a series of such analogues. Previous attempts to synthesize (E)-5-(2-nitrovinyl)uridine (2a) had failed because of the use of unsuitable protecting groups, as the nitrovinyl side-chain proved to be unstable to base. However, we found that acid deprotection could be achieved and thus we here describe the synthesis and antiviral properties of the ribo- and 2'-deoxyribo-nucleosides of (E)-5-(2-nitrovinyl)uracil.

RESULTS AND DISCUSSION

In a previous paper we described two initial routes to the synthesis of $2a.^7 2', 3'-0$ -Isopropylideneuridine ($\underline{3}$) can be hydroxymethylated at the

5-position 8,9 and the resulting nucleoside $\underline{4}$ then oxidized using

pyridinium dichromate in dichloromethane and dimethylformamide. During the generation of the nitrovinyl side chain from 5, the 5'-hydroxyl group was protected as the acetyl ester to give 6 which was not isolated but was deprotected with acid to 7. Attempts to remove the 5'-O-acetyl moiety with potassium carbonate/methanol or ammonia/methanol were not successful.

Alternatively, we found that (E)-5-(2-nitroviny1)-2,4- dimethoxypyrimidine (8) could be condensed with the sugar

 $1-\underline{O}$ -acetyl-2,3,5-tri- \underline{O} -benzoyl- \underline{B} - \underline{D} -ribofuranose to give $\underline{9}$. Although this could be demethylated at C-4 to give compound $\underline{10}$, the benzoyl sugar protecting groups could not be removed without the destruction of the nitrovinyl side-chain.

It was therefore decided to protect the sugar with an acid labile protecting group. Compound 5 was protected as its t-butyldiphenylsilyl ether and compound 11 was obtained in good yield. Under the conditions reported previously for the generation of the nitrovinyl side-chain, namely nitromethane and triethylamine followed by treatment with acetic anhydride, the nitrovinyl nucleoside 12 was obtained. This was then deprotected with 50% aqueous trifluoroacetic acid to give 2a as a pale yellow crystalline solid.

Commercially available 5-hydroxymethyluracil 10 (13) was used as the starting material for the preparation of the 2'-deoxynucleoside, 2b. This base was oxidised by aqueous potassium persulphate to 5-formyluracil $(14).^{11}$ procedure 12 published synthesis for the 5-formy1-2'-deoxyuridine starts from the dimethyl acetal of 5-formyluracil, obtained by the action of methanol and p-toluene sulphonic acid on 14. This is then condensed with the chlorosugar 2-deoxy-3,5-di- \underline{o} - \underline{p} -toluoyl- $\underline{\alpha}$ - \underline{D} - $\underline{erythro}$ -pentofuranosyl chloride (15) chloroform 13 to give the α and β of 5-formyl-3',5'-di-Q-p-toluoyl-2'-deoxyuridine (16 and 17 respectively). We were unable to repeat the preparation of the dimethyl acetal, 14 each time we obtained a good recovery of 5-formyl uracil. As an alternative, the bis(trimethylsilyl) derivative of 14 was reacted directly with the chlorosugar 15. The α and β anomers of the product were partially separated by fractional crystallization from acetone although the overall

yield of pure separated anomers was not high.

The p-toluoyl protecting groups of the pure β anomer $\underline{17}$ were then removed using sodium methoxide in methanol and the free 3'- and 5'-hydroxyl groups were then immediately reprotected as their t-butyldimethylsilyl ethers by t-butyldimethylchlorosilane to give the bis(TBDMS) nucleoside $\underline{18}$.

Compound 19 was then readily obtained using the standard method for the generation of the nitrovinyl side-chain and this could then be deprotected to give the required nucleoside 2b by acid hydrolysis using p-toluene sulphonic acid in methanol.

BIOLOGICAL RESULTS

(E)-5-(2-Nitrovinyl)uridine ($\underline{2a}$) was found to be inactive against HSV-2, HCMV and HIV with an IC₅₀ (μ M) > 100 μ M and for VZV > 40 μ M.

(E)-5-(2-Nitroviny1)-2'-deoxyuridine ($\underline{2b}$) was found to have an IC₅₀ (μ M) > 100 against HSV-2, HCMV, HIV and influenza-A and > 40 against VZV. Cytotoxicity (CCID₅₀) in vero cells = 72 μ M.

EXPERIMENTAL

Ultraviolet spectra were recorded with a Perkin Elmer spectrophotometer and were run in spectroscopic grade ethanol. Mass spectra were determined with a Kratos MS80 mass spectrometer with a DS55 data system employing automatic digital readout of data. For Fast Atom 3-NOBA matrix with Na doping Bombardement (FAB) а 3-mercapto-1,2-propanediol matrix were used. The 1H-NMR (s:singlet, d:doublet, t:triplet, b:broad, m:multiplet) were recorded on either a Jeol FX90 (90 MHz) or a Jeol GX270 (270 MHz) spectrometer. Precoated Merck silica gel 60 F₂₅₂ plates were used for TLC and the spots were examined with a UV light (254 nm) and a sulphuric acid-cysteine spray. Column chromatography was performed using Kieselgel 60, 70-230 mesh ASTM, type 7734, supplied by E. Merck A.G., Darmstadt, Germany. Columns were packed under gravity. Pyridine and triethylamine were heated under reflux over CaH_2 and then distilled. THF was dried with potassium/benzophenone then distilled.

 $\frac{5'-O-(tert-Butyldiphenylsilyl)-5-formyl-2',3'-O-isopropylideneuridine}{(11)}$ To a stirred solution of 5-formyl-2',3'-O-isopropylideneuridine (3.00 g, 9.60 mmol) in dry pyridine (40 ml) was slowly added a solution of tert- butyldiphenylchlorosilane (3.17 g, 11.53 mmol) in dry pyridine (15 ml). After stirring at room temperature for 10 hours the solution was evaporated to dryness $in\ vacuo$ and the resulting gum purified by column chromatography with elution in chloroform to give the product as a white foam (4.10 g, 78%). UV λ_{max} 292.0 nm, ϵ = 8350. 1 H-NMR δ (DMSO-d₆) 11.80(1-H,bs,N-H), 9.72(1-H,s,CHO). 8.48(1-H,s,H-6), 7.80-7.20(10-H,m,2 Ph), 5.84(1-H,d,H-1'), 5.03(1-H,m,H-2'), 4.62(1-H,m,H-3'), 4.25(1-H,m,H-4'), 3.84(2-H,m,H-5'), 1.47(3-H,s,CH₃), 1.26(3-H,s,CH₃), 0.97(9-H,s, t Bu). FAB mass spectrum (3-NOBA) m/e 493 (M- t Bu)+, 551 (M+H)+. Elemental analysis C₂₉H₃₄N₂O₇Si₂ calculated C, 63.25; H, 6.22; N, 5.08; found C, 63.0; H, 6.1; N,5.35.

5'-O-(tert-Butyldiphenylsilyl)-2',3'-O-isopropylidene-(E)-5-(2-nitrovinyl) uridine (12) To a solution of 11 (4.00 g, 7.26 mmol) in ethanol (100 ml) and nitromethane (80 ml) was added triethylamine (40 ml). After 2 hours at room temperature, TLC in 85:15 toluene/acetone showed complete conversion to a slower running nucleoside. The reaction mixture was evaporated to dryness in vacuo and acetic anhydride (100 ml) added. After 5 hours at room temperature the solution was once again evaporated to dryness in vacuo, coevaporated with methanol (3 x 25 ml) and the product isolated by short column chromatography as a yellow foam (3.91 g, 91%). UV λ_{max} 329.0 nm, ϵ = 17670. $^1\text{H-NMR}$ δ (DMSO-d₆) 11.97(1-H,s,N-H), 8.45(1-H,s,H-6), 8.19(1-H,d,vinylic H,J=14Hz), 7.84(1-H,d,vinylic H,J=14Hz), 7.75-7.25(10-H,m,2 Ph), 5.78(1-H,d,H-1'), 5.00(1-H,m,H-2'), 4.68(1-H,m,H-3'), 4.28(1-H,m,H-4'), 3.92(2-H,m,H-5'), 1.50(3-H,s,CH₃), 1.26(3-H,s,CH₃), 0.95(9-H,s, the sum of the color of

(E)-5-(2-Nitrovinyl)uridine (2a) A solution of 12 (1.00 g, 1.68 mmol) in 50% aqueous trifluoroacetic acid (50 ml) was stirred for 3 hours at room temperature after which time TLC in 90:10 chloroform/methanol showed total conversion to a more polar nucleoside. This was isolated by column chromatography with elution in 90:10 chloroform/methanol then recrystallized from ethanol to give the product as a pale yellow powder

(0.27 g, 50%). mp 231-233 °C. UV λ_{max} 333.0 nm, ϵ = 17400. $^1\text{H-NMR}$ $\delta(\text{DMSO-d}_6)$ 11.90(1-H,s,N-H), 8.68(1-H,s,H-6), 8.18(1-H,d,vinylic H,J=14 Hz), 7.30(1-H,d,vinylic H,J=14Hz), 5.75(1-H,d,H-1'), 5.60-4.80(3-H,m,3 x OH), 4.20-3.80(3-H,m,H-2',H-3',H-4'), 3.70-3.50(2-H,m,H-5'). FAB mass spectrum (3-mercapto-1,2-propanediol) m/e 424 (M+matrix+H) $^+$. Elemental analysis $C_{11}H_{13}N_{30}$ 8 calculated C, 41.91; H, 4.16; N, 13.33; found C, 42.1; H, 4.3; N, 13.0.

5-Formyl-3',5'-di-0-p-toluoyl-2'-deoxyuridine (17) 5-Formyluracil (1.00 g, 7.14 mmol) in hexamethyldisilazane (10 ml) and chlorotrimethylsilane (10 ml) was heated under reflux until a clear solution was obtained. The solution was evaporated to dryness in vacuo under high vacuum and the resulting oil then dissolved in chloroform (100 ml). To this stirred solution was added 15 (2.80 g, 7.20 mmol) and the solution stirred at room temperature for 20 hours then extracted with aqueous sodium bicarbonate (3 x 100 ml), saturated NaCl and dried (MgSO₄). The anomer mixture was purified by column chromatography with elution in a chloroform/methanol 100:0 to 95:5 gradient and the anomers partially separated by fractional crystallization from acetone to give 0.5 g of each pure anomer, total yield of pure separated anomers 1.00 g (29%). For the β anomer (17): mp 115-118 °C (Lit¹² 195-196 °C). UV λ_{max} 293.0 nm, ϵ = 9740. ¹H-NMR δ (DMSO-d₆) 11.87(1-H,s,N-H), 9.70(1-H,s,CHO), 8.42 (1-H,s,H-6), 7.93-7.85(4-H,m,arom), 7.37-7.28(4-H,m,arom), 6.22(1-H,t,m)H-1'), 5.38(1-H,s,H-3'), 4.61(3-H,m,H-4',H-5'), 2.39(3-H,s, CH_3), 2.37 $(3-H,s,CH_3)$. Elemental analysis $C_{26}H_{24}N_2O_8$ calculated C, 63.48; H, 4.91; N, 5.68; found C, 63.2; H, 5.0; N, 5.5.

3',5'-bis(tert-Butyldimethylsilyl)-5-formyl-2'-deoxyuridine (18) To a stirred solution of 17 (0.30 g, 0.61 mmol) in dry methanol (80 ml) was added a solution of sodium (0.1 g) in dry methanol (20 ml). After 3 hours at room temperature the solvent was removed in vacuo and the solid coevaporated with dry pyridine (2 x 30 ml) then suspended in dry pyridine (40 ml) and tert-butyldimethylchlorosilane (0.92 g, 6.10 mmol) added. After 3 days at room temperature the solvent was removed in vacuo to give an oil from which the product was isolated by column chromatography with elution in 96:4 dichloromethane/ethanol to give the product as a white foam (0.22 g, 79%). UV $\lambda_{\rm max}$ 292.0 nm, ϵ =10550. ¹H-NMR δ (DMSO-d₆) 11.84(1-H,s,N-H), 9.79(1-H,s,CHO), 8.32(1-H,s,H-6), 6.04(1-H,t,H-1'), 4.35(1-H,m,H-3'), 3.92(1-H,m,H-4'), 3.78(2-H,m,H-5'), 2.27(2-H,m,H-2'), 0.86(18-H,s,2 ^tBu), 0.07(12-H,s,4 SiMe₃). FAB mass spectrum m/e 485 (M+H) +, 507 (M+Na) +. Elemental analysis C₂₂H₄₀N₂O₆Si calculated C, 57.86; H, 8.83; N, 6.13; found C, 57.8; H, 8.9; N, 6.0.

3',5'-bis-(tert-Butyldimethylsilyl)-(E)-5-(2-nitrovinyl)-2'-deoxyuridine (19) To a stirred solution of 18 (0.37 g, 0.76 mmol) in dry ethanol (10 ml) were added nitromethane (8 ml) and triethylamine (8 ml) and the solution stirred for 2 hours then evaporated to dryness in vacuo and coevaporated twice with toluene. To the resulting foam were added acetic anhydride (10 ml) and triethylamine (0.50 ml) and the solution stirred overnight. The solution was taken to dryness and the product isolated by column chromatography with elution in dichloromethane/methanol 95:5 followed by recrystallization from ethanol to give the product as yellow crystals (0.24 g, 56%). mp 109-112 C. UV λ_{max} 331.0nm, ϵ =18240. ¹H-NMR δ (DMSO-d₆) 11.94(1-H,s,N-H), 8.35(1-H,s,H-6), 8.20(1-H,d,vinylic H,J=13Hz), 7.92(1-H,d,vinylic H,J=13Hz), 6.10(1-H,t,H-1'), 4.37(1-H,

m,H-3'), 3.84(1-H,m,H-4'), 3.75(2-H,m,H-5'), 2.30(2-H,m,H-2'), 0.87 (18-H,s,2 $^{\rm t}$ Bu), 0.08(12-H,d,2 SiMe₃). FAB mass spectrum m/e 528 (M+H) $^{\rm t}$. Elemental analysis C₂₅H₄₁N₃O₇Si calculated C, 52.34; H, 7.83; N, 7.96; found C, 52.45; H, 7.9; N, 8.1.

(E)-5-(2-Nitroviny1)-2'-deoxyuridine (2b) To a solution of 19 (0.15 g, 0.284 mmol) in dry methanol (15 ml) was added p-toluenesulphonic acid (0.5 g). After 2 hours at room temperature, TLC in 90:10 chloroform/ methanol showed the appearence of a new nucleoside which was isolated by short column chromatography and recrystallization from acetone/hexane to give a pale yellow powder (0.065 g, 76%). mp 186-188 °C. UV λ_{max} 332.0 nm, ∈=30010. ¹H-NMR δ (DMSO-d₆) 11.89(1-H,s,N-H), 8.60(1-H,s,H-6), 8.18 (1-H,d,vinylic H,J=13Hz), 7.91(1-H,d,vinylic H,J=13Hz), 6.09(1-H,d,H-1'), 5.30(1-H,d,3'-OH), 5.16(1-H,t,5'-OH), 4.25(1-H,t,H-3'), 3.81(1-H,d,H-4'), 3.66(1-H,m,H-5'), 2.20(2-H,t,H-2'). FAB mass spectrum (3-mercapto-1,2-propanediol) m/e 408 (M+matrix+H)⁺. Elemental analysis C₁₁H₁₃N₃O₇ calculated C, 44.15; H, 4.38; N, 14.04; found C, 43.99; H, 4.34; N, 13.61.

ACKNOWLEDGEMENTS

The authors wish to thank the Wellcome Company and the Minesterio de Educacion y Cienca for grants for this work (to RFW and VB respectively) and to the Wellcome Company for performing the biological testing.

REFERENCES

- P.J. Barr, A.S. Jones and R.T. Walker, J. Chem. Soc. Perkin Trans., 1981, 1, 1665
- E.De Clercq, J. Descamps, P.De Somer, P.J. Barr, A.S. Jones and R.T. Walker, Proc. Natl. Acad. Sci. USA, 1979, 76, 2947
- E.De Clercq, J. Descamps, P.C. Maudgal, L. Missotten, R. Leyten, G. Verhelst, A.S. Jones, R.T. Walker, R. Busson, H. Vanderhaeghe and P.De Somer in 'Developments in Antiviral Therapy', p21, Ed. L.H. Collier and J. Oxford, Academic Press, 1980
- 4. E.De Clercq and R.T. Walker, Pharm. Ther., 1984, 26, 1
- A. Kumar, M. Lewis, S. Shimizu, R.T. Walker, R. Snoeck and E.De Clercq, Antiviral Chemistry and Chemotherapy, 1990, 1, 35
- R. Kumar, L. Xu, E.E. Evans, C.I. Wiebe, D.R. Tovell, D.L. Tyrell and J.M. Allan, J. Med. Chem., 1990, 33, 717
- 7. R.F. Whale, P.L. Coe and R.T. Walker, In Press
- 8. K.H. Scheit, Chem. Ber., 1966, 99, 3884
- W.V. Armstrong, G. Witzel and F. Eckstein in 'Nucleic Acid Chemistry', Part 3, p65, Ed L.B. Townsend and R.S. Tipson, 1986
- 10. For example, Aldrich Chemical Co, Ltd
- 11. R. Brossmer and D. Ziegler, Tetrahedron Letters, 1966, 48, 5253
- A. Kamph and M.P. Mertes in 'Nucleic Acid Chemistry', Ed. L.B. Townsend and R.S. Tipson, Part 1, p355-357, 1978
- A.J. Hubbard, A.S. Jones and R.T. Walker, Nucleic Acids Research, 1984, 12, 6827
- 14. E.C. Ressner, A. Kamph and M.P. Mertes in 'Nucleic Acid Chemistry', Ed. L.B. Townsend and R.S. Tipson, Part 1, p89-91, 1978

Received 9/3/91 Accepted 11/15/91